Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: Prospective controlled study

Australian and New Zealand Journal of Psychiatry

Volumn 43, Issue 9, 2009, Pages 846-854

  Galbally, Megan ^a   Lewis, Andrew ^b   Lum, Jarrad ^b   Buist, Anne ^c  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antidepressants; Discontinuation; Pregnancy; Selective serotonin re uptake inhibitor

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIANSERIN; MIRTAZAPINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DELIVERY; DEPRESSION; DRUG WITHDRAWAL; FEEDING; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; JAUNDICE; NERVOUSNESS; NEWBORN CARE; NEWBORN DISEASE; PREGNANCY; PRENATAL DRUG EXPOSURE; QUESTIONNAIRE; RISK ASSESSMENT; SEROTONIN SYNDROME; SLEEP; SNEEZING; THIRD TRIMESTER PREGNANCY; TREMOR;

ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; SEROTONIN;

EID: 69449094639     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670903107583     Document Type: Article

References (36)

1. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: A systematic review ofpre valence and incidence. Obstet Gynecol 2005; 106:1071-1083.
2. Austin MP, Kildea S, Sullivan E. Maternal mortality and psychiatric morbidity in the perinatal period: Challenges and opportunities for prevention in the Australian setting. Med J Aust 2007; 186:364-367.
3. Austin MP. To treat or not to treat: Maternal depression, SSRI use in pregnancy and adverse neonatal effects. Psychol Med 2006; 25:1-8.
4. Hay DF, Pawlby S, Waters CS, Sharp D. Antepartum and postpartum exposure to maternal depression: Different effects on different adolescent outcomes. J Child Psychol Psychiatry 2008; 49:1079-1088.
5. Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA. Pregnancy, delivery, and neonatal complications in a population cohort ofwomen with schizophrenia and major affective disorders. Am J Psychiatry 2005; 162:79-91.
6. Field TM. Early interactions between infants and their postpartum depressed mothers. Infant Behav Dev 2002; 25: 25-29.
7. Cohen LS, Altshuler LL, Harlow BL et al. Relapse ofmajor depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499-507.
8. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63:898-906.
9. Andrade SE, Raebel MA, Brown J et al. Use of antidepressant medications during pregnancy: A multisite study. Am J Obstet Gynecol 2008; 198(2):194.e1-5.
10. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158:312-316.
11. Wogelius P, Norgaard M, Gislum M et al. Maternal use of selective serotonin reuptake inhibitors and risk ofcongenital malformations. Epidemiology 2006; 17:701-704.
12. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use ofselecti ve serotonin-reuptake inhibitors and the risk ofbirth defects. N Engl J Med 2007; 356:2675-2683.
13. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84:23-27.
14. Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk ofpersistent pulmonary hypertension ofthe newborn. N Engl J Med 2006; 354:579-587.
15. Andrade SE, McPhillips H, Loren D et al. Antidepressant medication use and risk ofpersistent pulmonary hypertension ofthe newborn. Pharmacoepidemiol Drug Saf 2009; 18:246-252.
16. Casper RC, Fleisher BE, Lee-Ancajas JC et al. Follow-up of children ofdepressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142:402-408.
17. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156:1129-1132.
18. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158:312-316.
19. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160:173-176.
20. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113:368-375.
21. Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA 2007; 293:2372-2383.
22. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage ofantidepre ssant medications. Am J Psychiatry 2003; 160:993-996.
23. Ter Horst PG, Jansman FG, van Lingen RA, Smit JP, de Jong-van den Berg LT, Brouwers JR. Pharmacological aspects ofneonatal antidepressant withdrawal. Obstet Gynecol Surv 2008; 63:267-279.
24. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010-1015.
25. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90:288-291.
26. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics offluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73:330-337.
27. Besunder JB, Blumer JL. Neonatal drug withdrawal syndromes. In: Koren G, ed. Maternal-fetal toxicology: A clinicians guide, 3rd edn. New York: Marcel Dekker, 2001:347-372.
28. Ali A, Taguchi N, Einarson A. Neonatal poor adaptation syndrome following in utero exposure to antidepressants. In: Koren G, ed. Medication safety in pregnancy and breastfeeding. USA: McGraw Hill, 2007:159-162.
29. Rampono J, Proud S, Hackett LP, Kristensen JH, Ilett KF. A pilot study ofnewer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol 2004; 7:329-334.
30. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988; 8:77-100.
31. AmericanPsychiatricAssociation. Diagnostic and statistical manual of mental disorders: DSM IV, 4th edn. Washington, DC: American Psychiatric Association, 1994.
32. Bezchlibnyk-Butler KZ, Jeffries JJ, eds. Clinical handbook of psychotropic drugs, 16th edn. Seattle: Hogrefe and Huber, 2006.
33. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 1998; 44:77-87.
34. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis. Lancet 2005; 365(9458):482-487.
35. Warner A. Drug use in the neonate: Interrelationships of pharmacokinetics, toxicity and biochemical maturity. Clin Chem 1986; 32:721-727.
36. Robinson M, Robertson D eds, Practical paediatrics, 3rd edn. UK: Churchill Livingstone, 1994.